Based on the Aprea Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Aprea Therapeutics Inc is USD 15.50 over the next 12 months. Aprea Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aprea Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Aprea Therapeutics Inc’s stock price was USD 5.17. Aprea Therapeutics Inc’s stock price has changed by -9.77% over the past week, -15.52% over the past month and +32.29% over the last year.
No recent analyst target price found for Aprea Therapeutics Inc
No recent average analyst rating found for Aprea Therapeutics Inc
Company Overview Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania. Address: 3805 Old Easton Road, Doylestown, PA, United States, 18902 Read Less
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials f...Read More
Frequently Asked Questions About Aprea Therapeutics Inc (APRE) Stock
Based on ratings from 2 analysts Aprea Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on APRE's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for APRE is USD 15.50 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 11.
APRE stock's Price/Earning ratio is 0.48.
Our analysis grades APRE stock's Price / Earning ratio at C+. This means that APRE stock's Price/Earning ratio is above 22% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this APRE may be undervalued for its sector.
The last closing price of APRE's stock was USD 5.17.
The most recent market capitalization for APRE is USD 0.03B.
Based on targets from 2 analysts, the average taret price for APRE is projected at USD 15.50 over the next 12 months.
This means that APRE's stock price may go up by +199.81% over the next 12 months.
We can't find any ETFs which contains Aprea Therapeutics Inc's stock.
As per our most recent records Aprea Therapeutics Inc has 7 Employees.
Aprea Therapeutics Inc's registered address is 535 Boylston St., Boston, MA, United States, 02116.
You can get more information about it from Aprea Therapeutics Inc's website at https://atrinpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APRE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
